ReviewFrontiers in oncology2026
Targeting TGF-β-driven fibrotic, epigenetic remodeling and Bax/Bcl-2 through polyphenol-exercise synergy: molecular implications for biomechanical impairment and rehabilitation in cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimizing human activity through biomechanical efficiency is central not only to enhancing physical performance but also to restoring functional capacity in disease states. In cancer patients, tumor progression and treatment-related toxicities induce profound molecular and epigenetic alterations within the tumor-muscle-matrix axis, leading to fibrosis, muscle wasting, neuromuscular dysfunction, and impaired activity biomechanics. While exercise training remains a cornerstone intervention for improving activity quality and physical resilience, emerging evidence suggests that targeted nutritional strategies, particularly polyphenol supplementation, may modulate key oncogenic and fibrotic signaling pathways. Polyphenols, a diverse class of plant-derived bioactive compounds, exert potent antioxidant, anti-inflammatory, and epigenetic regulatory effects that influence TGF-β/SMAD signaling, microRNA expression, extracellular matrix remodeling, and mitochondrial function in cancer and skeletal muscle tissues. This review examines the molecular and epigenetic convergence of polyphenols and exercise in reprogramming tumor-muscle-matrix crosstalk, and discusses how these mechanisms translate into biomechanical dysfunction, injury susceptibility, and rehabilitation outcomes in cancer patients. By integrating data from preclinical oncology models, clinical studies in cancer populations, and mechanobiological research, we explore how combined nutritional-mechanical interventions may attenuate cancer-associated fibrosis, modulate inflammatory and epigenetic signatures, preserve muscle integrity, and improve functional activity capacity. We further propose that selective modulation of fibrotic and epigenetic pathways may reduce biomechanical impairment, enhance rehabilitation responsiveness, and mitigate injury risk during cancer survivorship. The concept of molecular-mechanobiological synergy provides a translational framework linking tumor biology to functional activity outcomes. Future interdisciplinary research should prioritize longitudinal, multimodal studies integrating epigenetic biomarkers, tumor-derived signaling mediators, and advanced biomechanical profiling in oncology settings to validate and personalize combined exercise-polyphenol strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.